0001493152-21-032025.txt : 20211220
0001493152-21-032025.hdr.sgml : 20211220
20211220160023
ACCESSION NUMBER: 0001493152-21-032025
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211216
FILED AS OF DATE: 20211220
DATE AS OF CHANGE: 20211220
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Opaleye Management Inc.
CENTRAL INDEX KEY: 0001595855
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36694
FILM NUMBER: 211505195
BUSINESS ADDRESS:
STREET 1: ONE BOSTON PLACE
STREET 2: SUITE 2600
CITY: BOSTON
STATE: MA
ZIP: 02108
BUSINESS PHONE: 617-904-9195
MAIL ADDRESS:
STREET 1: ONE BOSTON PLACE
STREET 2: SUITE 2600
CITY: BOSTON
STATE: MA
ZIP: 02108
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Protara Therapeutics, Inc.
CENTRAL INDEX KEY: 0001359931
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 204580525
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 345 PARK AVENUE SOUTH
STREET 2: 3RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10010
BUSINESS PHONE: 646-844-0337
MAIL ADDRESS:
STREET 1: 345 PARK AVENUE SOUTH
STREET 2: 3RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10010
FORMER COMPANY:
FORMER CONFORMED NAME: ArTara Therapeutics, Inc.
DATE OF NAME CHANGE: 20200110
FORMER COMPANY:
FORMER CONFORMED NAME: PROTEON THERAPEUTICS INC
DATE OF NAME CHANGE: 20060420
4
1
ownership.xml
X0306
4
2021-12-16
0
0001359931
Protara Therapeutics, Inc.
TARA
0001595855
Opaleye Management Inc.
ONE BOSTON PLACE
SUITE 2600
BOSTON
MA
02108
0
0
1
0
Common Stock, par value $0.001 per share
2021-12-16
4
P
0
6500
6.4108
A
2493206
I
By Opaleye, L.P.
Common Stock, par value $0.001 per share
2021-12-16
4
P
0
1063
6.4108
A
103710
I
By Managed Account
Common Stock, par value $0.001 per share
2021-12-17
4
P
0
2300
6.60
A
2495506
I
By Opaleye, L.P.
Common Stock, par value $0.001 per share
2021-12-17
4
P
0
490
6.60
A
104200
I
By Managed Account
Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund.
Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account.
The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $6.41. The range of purchase prices on the transaction date was $6.35 to $6.49 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $ 6.60. The range of purchase prices on the transaction date was $6.40 to $6.70 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
Opaleye Management Inc., /s/ James Silverman, President
2021-12-20